Overview

Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)

Status:
Completed

Trial end date:
2005-09-01

Target enrollment:

Participant gender:

Summary

The primary objective of this placebo-controlled EEC study is to determine the time to onset of action of ciclesonide, applied as a nasal spray (200 mg, once daily) in patients with SAR.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Ciclesonide